Gene Therapy For Severe Retinitis Pigmentosa Secures EMA PRIME Status
Janssen and MeiraGTx say their investigational product is the only treatment for x-linked retinitis pigmentosa in development to win a place on the European Medicines Agency’s priority medicines scheme.
You may also be interested in...
Nine of the 70 medicines for unmet medical needs that have to date won a place on the European Medicines Agency’s PRIME scheme are now approved for sale in the EU, and two more approvals are expected soon. Meanwhile, most applications for a "priority medicine" designation are still missing the mark.
Bavencio, Taltz, Cosentyx, and Opdivo plus Yervoy were this week also the subject of final recommendations from the health technology assessment body, NICE, on whether or not they should be used on the National Health Service for certain indications.
Janssen and UK health technology assessment body NICE are being urged to sit down together and agree a suitable price for using Zytiga as a first-line treatment for advanced prostate cancer.